rs10818488 — TRAF1 TRAF1-C5 rheumatoid arthritis variant

TRAF1-C5 — The Signal Between Two Inflammatory Sentinels

Two genes sit on chromosome 9q33-34, separated by roughly 10 kilobases of intergenic DNA: TRAF1, a signaling adapter that modulates NF-kB activation, and C5, the complement protein that bridges innate and adaptive immunity. The rs10818488 polymorphism lies exactly in this gap — a regulatory SNP¹¹ SNP
Single nucleotide polymorphism — a single-letter DNA difference that varies between people that is one of the most robust and well-replicated non-HLA risk loci for rheumatoid arthritis (RA) identified to date. The A allele, carried by approximately 42% of Europeans, confers measurably elevated RA risk and is associated with faster joint destruction in established disease.

The Mechanism

rs10818488 maps to the intergenic region approximately 10 kb from both the TRAF1 and C5 transcription start sites. It does not change any protein directly. Instead, it alters the local regulatory landscape: the A allele creates a binding site for EP300²² A allele creates a binding site for EP300
EP300 is a histone acetyltransferase that opens chromatin and activates transcription; binding at this locus appears to alter TRAF1 expression levels in immune cells, a histone acetyltransferase that remodels chromatin and activates transcription. Experimental evidence from monocytes confirms the functional direction: carriers of risk alleles at this locus express less TRAF1 protein³³ less TRAF1 protein
Paradoxically, reduced TRAF1 expression leads to more inflammation because TRAF1 normally sequesters LUBAC, the linear ubiquitin assembly complex; without sufficient TRAF1, LUBAC is released and drives stronger NF-kB activation upon stimulation and produce increased amounts of TNF and IL-6. TRAF1's role in NF-kB regulation is paradoxical: while it amplifies survival signaling through TNFR family members, it also suppresses excessive TLR/NLR responses by sequestering LUBAC. Lower TRAF1 expression tips this balance toward enhanced inflammatory cytokine output.

This creates a self-reinforcing loop in RA pathogenesis: reduced TRAF1 expression → amplified TNF production → further joint inflammation → progressive erosive disease. The A allele's association with radiographic damage progression reflects exactly this mechanism.

The Evidence

The TRAF1-C5 locus was first established as an RA risk locus by Plenge et al. in the New England Journal of Medicine⁴⁴ Plenge et al. in the New England Journal of Medicine
A landmark 2007 genome-wide association study with stepwise replication across Dutch, Swedish, and US cohorts (2007), with rs10818488 confirmed across 2,719 RA patients and 1,999 controls (OR 1.28, 95% CI 1.17–1.39, p = 1.40×10⁻⁸). The population-attributable risk — the fraction of RA cases attributable to this variant — was 6.1%, making it one of the most consequential non-HLA loci. A candidate gene study⁵⁵ candidate gene study
Using targeted genotyping of biologically plausible genes rather than genome-wide scanning replicated the finding across four independent sample sets: the A allele gave an OR of 1.26 overall, with AA homozygotes showing OR 2.06 (95% CI 1.42–2.98) compared with GG carriers.

A meta-analysis of 24 studies⁶⁶ meta-analysis of 24 studies
Pooling 22,682 RA cases and 23,493 controls confirmed the association in Europeans (OR 1.229, 95% CI 1.094–1.381, p=0.001) but not significantly in Asians, where the directional effect is reversed in some analyses — a genuine genetic heterogeneity reflecting different LD patterns at this locus across ancestries. An updated meta-analysis⁷⁷ updated meta-analysis
21 studies, 15,171 cases and 13,998 controls, with population-stratified analysis found the G allele is paradoxically protective in Europeans but a weak risk allele in Asians, consistent with the A allele's European-ancestry risk direction.

Beyond susceptibility, the A allele is associated with disease severity: carriers show greater radiographic joint damage progression over time (p=0.008). Association with higher disease activity scores has been replicated in Middle Eastern populations. The variant also extends to systemic lupus erythematosus, with an OR of 1.21 (95% CI 1.12–1.31, p=5.0×10⁻⁶) in Europeans in a separate meta-analysis⁸⁸ a separate meta-analysis.

Practical Actions

For AA homozygotes carrying two copies of the risk allele, the priority is early recognition of RA symptoms and baseline autoantibody testing — anti-CCP (ACPA) and rheumatoid factor — since the A allele's risk is predominantly expressed in seropositive, erosive RA. Joint stiffness lasting over 30 minutes in the morning, symmetric swelling of small hand joints, and unexplained fatigue are the key early warning signs. Because this locus also influences response to anti-TNF biologics (rs3761847, a nearby proxy SNP at the same locus, predicts anti-TNF outcomes), genotype information from this region may eventually guide biologic selection.

For the heterozygous AG genotype, the modestly elevated risk warrants awareness rather than aggressive clinical action, unless compounded by HLA-DRB1 shared epitope alleles or PTPN22 R620W carriage.

Interactions

rs10818488 and rs3761847 are the two most studied SNPs at the TRAF1-C5 locus, located approximately 10 kb apart in the same intergenic haplotype block. In most populations they are in high linkage disequilibrium and tag the same risk haplotype. The nearby rs3761847 G allele has been associated with poor response to anti-TNF therapy in RA, while rs10818488 A allele captures the overall susceptibility signal. Carrying risk alleles at both SNPs likely identifies the highest-risk individuals at this locus.

PTPN22 rs2476601 (R620W) is the strongest non-HLA non-TRAF1 RA susceptibility variant; combined carriage of PTPN22 A allele and TRAF1-C5 A allele substantially elevates RA risk beyond either alone through independent immune signaling pathways (T-cell signaling threshold versus NF-kB regulation). TNFAIP3 rs13207033, a protective NF-kB regulatory variant at the 6q23 locus, may partially offset TRAF1-C5 risk through independent A20-mediated NF-kB suppression.